Please assess the completion status of the following clinical trial:

Trial Title: Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Stage IIB-IV mycosis fungoides or Sezary syndrome, who have failed at least 1 standard systemic therapy or are not candidates for standard therapy.~2. Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center.~3. Age \> 18 years and \<= 75 years.~4. Karnofsky Performance Status \>= 70%.~5. Corrected DLCO \>= 40%~6. Left ventricle ejection fraction (LVEF) \> 30%.~7. ALT and AST must be \<= 3X normal. Total bilirubin \<= 3 mg/dL unless hemolysis or Gilbert's disease.~8. Estimated creatinine clearance \>= 50 ml/min.~9. Have a related or unrelated HLA-identical donor or one antigen/allele mismatched in HLA-A, B, C or DRB1.~10. Signed informed consent.~11. Patients with prior malignancies diagnosed \> 5 years ago without evidence of disease are eligible.~12. Patients with a prior malignancy treated \< 5 years ago but have a life expectancy of \> 5 years for that malignancy are eligible.~Donor Inclusion Criteria~1. Age \>=17.~2. HIV seronegative.~3. No contraindication to the administration of G-CSF.~4. Willing to have a central venous catheter placed for apheresis if peripheral veins are inadequate~Exclusion Criteria:~1. Uncontrolled active infection.~2. Uncontrolled congestive heart failure or angina.~3. Pregnancy or nursing patients will be excluded from the study.~4. Those who are HIV-positive will be excluded from the study due to high risk of lethal infection after hematopoietic cell transplantation.~Donor Exclusion Criteria~1. Serious medical or psychological illness.~2. Pregnant or lactating women are not eligible~3. Prior malignancies within the last 5 years except for non-melanoma skin cancers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Total lymphoid irradiation & anti-thymocyte immunoglobulin (Type: EXPERIMENTAL): TLI is administered from a 6 MeV linear accelerator in 80c- 120c Gy fractions. Anti-thymocyte-Globulin (ATG) is administered intravenously for a total dose of 7.5 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).